Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial

Broekhuijsen, Kim; Baaren, Gert Jan Van; Pampus, Maria G. van; Ganzevoort, Wessel; Sikkema, J.; Woiski, Mallory; Oudijk, Martijn A.; Bloemenkamp, Kitty W. M.; Scheepers, Hubertina; Bremer, Henk A.; Rijnders, Robbert J.P.; Loon, A.J. van; Perquin, Denise A. M.; Sporken, Jan; Papatsonis, Dimitri; Huizen, Marloes E. van; Vredevoogd, Corla B.; Brons, J. T. J.; Kaplan, Mesrure; Kaam, Anton H. van; Groen, Henk; Porath, Martina; Berg, Paul P. van den; Mol, Ben Willem J.; Franssen, Maureen; Langenveld, Josje

doi:10.1016/s0140-6736(14)61998-x

Cited by 152 publications

(144 citation statements)

References 19 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…123 Consequently, for women presenting between 34 and 37 weeks, we have replaced the values in NICE CG107 (see appendix I) 13 that were from the HYPITAT I study 124 to reflect maternal and neonatal outcomes measured in the HYPITAT II study. 126 The HYPITAT II study compared expectant monitoring for hypertensive disorders of pregnancy (including PE) in women between 34 and 37 weeks of gestation against induction within 2 days of presentation. In one arm of the trial, women were assigned to induction within 2 days.…”

Section: Maternal Outcomementioning

confidence: 99%

“…Two trials (HYPITAT I 124 and HYPITAT II 126 ) were identified that reported these characteristics separately, for women with gestational hypertension or PE who were randomised to immediate delivery (within 48 hours) and those who were randomised to expectant monitoring. The HYPITAT I study has been criticised on the basis of its composite outcome of maternal morbidity and for not including neonatal outcomes.…”

Section: Event Probabilitiesmentioning

confidence: 99%

“…The primary neonatal outcome for the HYPITAT II study 126 was the probability of neonatal respiratory distress syndrome. After appraising data from the HYPITAT II study, 126 and consulting clinical experts to determine whether or not neonatal morbidity had any probable effects on quality of life for mothers or neonates, the EAG decided only to model the rate of NICU admission to capture the effects of neonatal morbidity.…”

Section: Event Probabilitiesmentioning

confidence: 99%

“…After appraising data from the HYPITAT II study, 126 and consulting clinical experts to determine whether or not neonatal morbidity had any probable effects on quality of life for mothers or neonates, the EAG decided only to model the rate of NICU admission to capture the effects of neonatal morbidity. This decision was supported by three experts.…”

Section: Event Probabilitiesmentioning

confidence: 99%

“…There were very few events, with HELLP syndrome being the most common. 126 Experts indicated that there were unlikely to be any significant long-term differences in maternal morbidity based on data in the HYPITAT II trial. 126 …”

Section: Event Probabilitiesmentioning

confidence: 99%

See 4 more Smart Citations

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

Frampton

Jones

Rose

et al. 2016

Health Technol Assess

View full text Add to dashboard Cite

growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis. Health Technol Assess 2016;20(87).Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch ® ) and Current Contents ® / Clinical Medicine. This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/). Health Technology Assessment NICE TAR and DAREditorial contact: nihredit@southampton.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 14/69/05. The protocol was agreed in March 2015. The assessment report began editorial review in September 2015 and was accepted for publication in June 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The ...

show abstract

Section: Maternal Outcomementioning

confidence: 99%

Section: Event Probabilitiesmentioning

confidence: 99%

Section: Event Probabilitiesmentioning

confidence: 99%

Section: Event Probabilitiesmentioning

confidence: 99%

Section: Event Probabilitiesmentioning

confidence: 99%

See 3 more Smart Citations

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

Frampton

Jones

Rose

et al. 2016

Health Technol Assess

View full text Add to dashboard Cite

show abstract

The Hypertensive Disorders of Pregnancy

Leeman

Dresang

Fontaine

1954

JAMA

View full text Add to dashboard Cite

Preeclampsia Screening

Henderson

Thompson

Burda

et al. 2017

JAMA

105

View full text Add to dashboard Cite

IMPORTANCE Preeclampsia is a complex disease of pregnancy with sometimes serious effects on maternal and infant morbidity and mortality. It is defined by hypertension after 20 weeks' gestation and proteinuria or other evidence of multisystem involvement.OBJECTIVE To systematically review the benefits and harms of preeclampsia screening and risk assessment for the US Preventive Services Task Force.

show abstract

Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial

Cited by 152 publications

References 19 publications

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

The Hypertensive Disorders of Pregnancy

Preeclampsia Screening

Contact Info

Product

Resources

About